SHIELD THERAPEUTICS PLC ORD 1.5吧
排序:
评论时间
  • 评论时间
  • 发帖时间
阅读评论标题 作者 最后更新
25 0 公告 Interim results for the six months ended 30 Jun 25 SHIELD THERAPEUT资讯 08-21 19:10
28 0 公告 Q2 2025 Trading Update SHIELD THERAPEUT资讯 07-23 14:26
34 0 公告 Result of AGM SHIELD THERAPEUT资讯 05-23 00:24
33 0 公告 Audited results for the year ended 31 Dec 2024 SHIELD THERAPEUT资讯 04-24 14:38
33 0 公告 Licence Agreement in Japan for ACCRUFeR? SHIELD THERAPEUT资讯 04-22 15:40
36 0 公告 Q1 2025 Trading Update SHIELD THERAPEUT资讯 04-17 18:24
38 0 公告 ACCRUFeR? launched in Canada SHIELD THERAPEUT资讯 03-11 15:25
46 0 公告 PDMR Transaction Notification SHIELD THERAPEUT资讯 02-14 00:26
52 0 公告 Grant of Share Options SHIELD THERAPEUT资讯 02-13 15:17
48 0 公告 Unaudited full year trading update SHIELD THERAPEUT资讯 02-05 15:18
49 0 公告 Anders Lundstrom appointed CEO SHIELD THERAPEUT资讯 01-27 15:19
65 0 公告 Result of General Meeting & Total Voting Rights SHIELD THERAPEUT资讯 12-24 19:28
66 0 公告 Results of RetailBook Offer SHIELD THERAPEUT资讯 12-23 15:17
63 0 公告 Subscription by AOP Health to raise US$10 million SHIELD THERAPEUT资讯 12-06 19:33
82 0 公告 RetailBook Offer SHIELD THERAPEUT资讯 12-06 19:33
75 0 公告 Business Update SHIELD THERAPEUT资讯 11-21 15:17
64 0 公告 Q3 Trading Update SHIELD THERAPEUT资讯 10-29 15:08
63 0 公告 Results from Phase 3 paediatric study SHIELD THERAPEUT资讯 09-25 14:12
57 0 公告 Interim results SHIELD THERAPEUT资讯 09-04 14:47
71 0 公告 ACCRUFeR Approved by Health Canada SHIELD THERAPEUT资讯 08-27 15:19
59 0 公告 Notice of interim results SHIELD THERAPEUT资讯 08-14 15:10
64 0 公告 Unaudited Q2 2024 Trading Update SHIELD THERAPEUT资讯 07-24 15:18
65 0 公告 Directorate Change SHIELD THERAPEUT资讯 07-24 15:08
66 0 公告 $5.7m Milestone Monetization Agreement with AOP SHIELD THERAPEUT资讯 07-03 15:25
68 0 公告 Results of 2024 Annual General Meeting SHIELD THERAPEUT资讯 06-21 00:33
62 0 公告 New Drug Application for Accrufer in South Korea SHIELD THERAPEUT资讯 05-28 15:20
69 0 公告 Audited results for the year ended 31 Dec 2023 SHIELD THERAPEUT资讯 05-10 23:37
59 0 公告 Business Update for Q1 2024 SHIELD THERAPEUT资讯 04-30 15:07
66 0 公告 Notice of Results SHIELD THERAPEUT资讯 04-16 15:22
88 0 公告 Unaudited Full Year Trading Update SHIELD THERAPEUT资讯 02-21 16:08
62 0 公告 Appointment of new Chief Financial Officer SHIELD THERAPEUT资讯 01-09 16:11
86 0 公告 Q3 2023 U.S. Commercial Highlights SHIELD THERAPEUT资讯 12-07 16:11
91 0 公告 PDMR Transaction Notification SHIELD THERAPEUT资讯 11-28 02:32
102 0 公告 Abstract to be presented at Healthcare Conference SHIELD THERAPEUT资讯 10-20 18:52
88 0 公告 Chief Financial Officer Transition SHIELD THERAPEUT资讯 10-12 15:08
85 0 公告 Result of REX Retail Offer SHIELD THERAPEUT资讯 10-03 23:07
88 0 公告 Completion of SWK Financing SHIELD THERAPEUT资讯 10-03 15:10
88 0 公告 Block listing Interim Return SHIELD THERAPEUT资讯 10-03 15:09
78 0 公告 Successful completion of US$6.1m Equity Fundraise SHIELD THERAPEUT资讯 09-28 20:57
86 0 公告 REX Retail Offer SHIELD THERAPEUT资讯 09-28 15:11
77 0 公告 $20m secured debt facility &proposed equity raise SHIELD THERAPEUT资讯 09-28 15:09
76 0 公告 Interim results update and business update SHIELD THERAPEUT资讯 09-28 15:09
80 0 公告 Notice of Results and Change in reporting currency SHIELD THERAPEUT资讯 09-06 15:04
103 0 公告 Holding(s) in Company SHIELD THERAPEUT资讯 07-24 22:35
87 0 公告 Business Update and U.S. Q2 2023 Highlights SHIELD THERAPEUT资讯 07-20 15:18
95 0 公告 Results of 2023 Annual General Meeting SHIELD THERAPEUT资讯 06-29 01:32
94 0 公告 Grant of share options to the CEO SHIELD THERAPEUT资讯 06-06 18:17
95 0 公告 Holding(s) in Company SHIELD THERAPEUT资讯 06-01 19:03
153 0 公告 Holding(s) in Company SHIELD THERAPEUT资讯 06-01 19:03
109 0 公告 Total Voting Rights SHIELD THERAPEUT资讯 05-31 15:09
105 0 公告 2022 Annual Report and 2023 AGM Notice SHIELD THERAPEUT资讯 05-19 15:08
100 0 公告 Form 8 (OPD) - Shield Therapeutics plc SHIELD THERAPEUT资讯 05-18 23:19
128 0 公告 Rule 2.9 Announcement and TVR Update SHIELD THERAPEUT资讯 05-10 00:23
111 0 公告 Business Update and Unaudited Results SHIELD THERAPEUT资讯 04-27 15:04
105 0 公告 Notice of Results SHIELD THERAPEUT资讯 04-12 15:07
141 0 公告 Appointment of Chief Commercial Officer SHIELD THERAPEUT资讯 04-05 15:04
148 0 公告 Block Listing 6 Monthly Return SHIELD THERAPEUT资讯 03-31 15:03
324 0 公告 Price Monitoring Extension SHIELD THERAPEUT资讯 03-16 02:17
189 0 公告 Total Voting Rights Update SHIELD THERAPEUT资讯 02-28 16:20
168 0 公告 Price Monitoring Extension SHIELD THERAPEUT资讯 02-17 20:13
169 0 公告 Second Price Monitoring Extn SHIELD THERAPEUT资讯 02-17 20:13
154 0 公告 Second Price Monitoring Extn SHIELD THERAPEUT资讯 02-10 01:52
138 0 公告 Price Monitoring Extension SHIELD THERAPEUT资讯 02-10 01:50
155 0 公告 Second Price Monitoring Extn SHIELD THERAPEUT资讯 02-09 18:12
162 0 公告 Price Monitoring Extension SHIELD THERAPEUT资讯 02-09 18:08
142 0 公告 Full Year Trading Update SHIELD THERAPEUT资讯 02-09 17:32
199 0 公告 Holding(s) in Company SHIELD THERAPEUT资讯 01-13 19:37
138 0 公告 Holding(s) in Company SHIELD THERAPEUT资讯 01-12 23:51
130 0 公告 Holding(s) in Company SHIELD THERAPEUT资讯 01-12 23:21
182 0 公告 Partial AOP Loan Conversion SHIELD THERAPEUT资讯 01-10 02:19
146 0 公告 Holding(s) in Company SHIELD THERAPEUT资讯 01-10 01:11
147 0 公告 Holding(s) in Company SHIELD THERAPEUT资讯 01-10 01:01
124 0 公告 Result of General Meeting & Open Offer SHIELD THERAPEUT资讯 01-06 00:58
111 0 公告 PDMR Transaction Notification SHIELD THERAPEUT资讯 12-28 16:18
134 0 公告 Total Voting Rights Update SHIELD THERAPEUT资讯 12-28 16:05
125 0 公告 Publication of Circular &Notice of General Meeting SHIELD THERAPEUT资讯 12-16 16:18
132 0 公告 Successful completion of US$18.5m Equity Fundraise SHIELD THERAPEUT资讯 12-14 00:50
117 0 公告 Placing & Subscription to raise approx. US$18m SHIELD THERAPEUT资讯 12-13 16:20
109 0 公告 Collaborative Sales Agreement signed with Viatris SHIELD THERAPEUT资讯 12-13 16:18
发表新主题
悬赏提问
帖子不见了!怎么办?   
   请登录 登录 | 5秒注册 作者: 退出 
温馨提示: 1.根据《证券法》规定,禁止编造、传播虚假信息或者误导性信息,扰乱证券市场;2.用户在本社区发表的所有资料、言论等仅代表个人观点,与本网站立场无关,不对您构成任何投资建议。用户应基于自己的独立判断,自行决定证券投资并承担相应风险。《东方财富社区管理规定》

扫一扫下载APP

扫一扫下载APP
信息网络传播视听节目许可证:0908328号 经营证券期货业务许可证编号:913101046312860336 违法和不良信息举报:021-34289898 举报邮箱:jubao@eastmoney.com
沪ICP证:沪B2-20070217 网站备案号:沪ICP备05006054号-11 沪公网安备 31010402000120号 版权所有:东方财富网 意见与建议:021-54509966/952500